Stocksigma LogoStocksigma Logo

USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility

The USFDA conducted a Pre-Approval Inspection (PAI) at Gufic Biosciences Limited's manufacturing facility located in Indore, Madhya Pradesh, from 15th

USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility

Gufic Biosciences Ltd 路 Others (Uncategorized) 路 24 Oct 2026, 2:11 am

USFDA Issues Three Form 483 Observations for Gufic Biosciences' Indore Facility The USFDA conducted a Pre-Approval Inspection (PAI) at Gufic Biosciences Limited's manufacturing facility located in Indore, Madhya Pradesh, from 15th Oct'26 to 23rd Oct'26. Upon concluding the inspection, the regulator issued Form FDA 483 with three observations. The company stated it will work closely with the USFDA and remains committed to addressing all observations comprehensively within the stipulated timeframe.

Original exchange filing (PDF)

More announcements from Gufic Biosciences Ltd

All Gufic Biosciences Ltd announcements